Announcements Trials
Browse Landscape

Status

Terminated 5Withdrawn 3No longer available 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

nilotinib 4midostaurin 3venetoclax 2navitoclax 2fludarabine phosphate 2revumenib 1ponatinib 1magrolimab 1gilteritinib 1fludarabine 1eryaspase 1enasidenib 1asparaginase erwinia chrysanthemi recombinant 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Mycophenolic Acid 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bone Marrow Transplantation 1Asparaginase 1AP 1903 reagent 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × magrolimab × Other hematologic neoplasm × Clear all
NCT05627466 2024-02-15

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Gilead Sciences

No longer available
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡